BioGaia AB (NASDAQ Stockholm: BIOG) will host a Capital Markets Day in London on December 8, 2026. The Capital Markets Day will be held as an in-person event in London, and the presentations will also be broadcast live.
During the event, members of BioGaia's leadership team, including Theresa Agnew, President and Chief Executive Officer; Alexander Kotsinas, Executive Vice President and Chief Financial Officer; and Gianfranco Grompone, Chief Scientific Officer, will provide insights into the company's strategy.
The programme will cover BioGaia's strategic progress and long-term vision, science and innovation pipeline, growth opportunities, go-to-market strategy, operational and manufacturing capabilities, financial framework, and long-term value creation. The event will conclude with a Q&A session.
Further programme and webcast details will be shared with registered participants closer to the event. For investors and analysts, please fill in your name, title, organization, and attendance preference (in person or via livestream) here: Register to BioGaia’s Capital Markets Day 2026 – Fill out form.
If you have any questions regarding the event, please contact us at cmd2026@biogaia.com
Follow us:
Subscribe to BioGaia press releases here
LinkedIn here
Contacts:
Alexander Kotsinas, Chief Financial Officer
Email alexander.kotsinas@biogaia.com
Phone +46 735 00 11 11
Mikaela Idermark Stern, Corporate Communications
Email mikaela.idermark.stern@biogaia.com
Phone +46 730 95 61 50
About BioGaia
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com